Back


03/01/2020
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
Copenhagen, Denmark, January 3, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces 12- month interim data from an open-label extension of a phase 2/3 study of arimoclomol, an investigational product candidate in development for Niemann-Pick disease Type C (NPC). [...]

Download the pdf file





X

X